31 results
Thumbnail

D1.391 - Pharmacist-led Risk-based β-Lactam Challenges in Patients with Penicillin Allergy: Impact on Antibiotic Days

Thumbnail

D1.379 - Six-year data evaluating the results of skin tests and provocation tests with quinolones in patients with a history of quinolone allergy

Thumbnail

D1.380 - Hypersensitivity reactions with proton pump inhibitors: five years of clinical experience

Thumbnail

D1.381 - Antibiotic Allergy De-labelling in Children: Outcomes of Drug Provocation Testing and Feasibility of Non-Specialist Pathways to de-labelling

Thumbnail

D1.382 - Vitamin K–Induced Anaphylaxis: A Case Series from a Tertiary Hospital in Manila, Philippines (2024–2025)

Thumbnail

D1.384 - Safe Sulfonamide Delabeling in HIV-Negative Adults: Real-World Evidence with TMP-SMX Oral Challenge and SULF-FAST

Thumbnail

D1.385 - Lamotrigine-induced Stevens-Johnson syndrome in a pediatric patient with Takayasu arteritis: the steroid paradox

Thumbnail

D1.386 - Adverse infusion reactions to biologicals in the treatment of inflammatory bowel diseases

Thumbnail

D1.387 - Long-term Follow-up Outcomes of Patients Undergoing Desensitization for Non-Immediate Hypersensitivity Reactions Associated with Lenalidomide

Thumbnail

D1.388 - Aspirin maintenance after boost with dupilumab in aspirin-exacerbated respiratory disease

Thumbnail

D1.389 - Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis Due to Allopurinol With Subsequent Sensitization to Brentuximab: A Case Report

Thumbnail

D1.390 - Hypersensitivity Reactions to Biological Agents in a Tertiary Hospital: A 3.5-Year Retrospective Study

Thumbnail

D1.392 - Drug-Induced Hypersensitivity Syndrome Associated with β-Lactams and Hemophagocytic Lymphohistiocytosis: Overlapping Disorders or a Causal Relationship?

Thumbnail

D1.393 - Safety of Aspirin Oral Provocation in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study